A Phase 3 Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ALN TTRSC in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)
Phase of Trial: Phase III
Latest Information Update: 27 Jul 2017
At a glance
- Drugs Revusiran (Primary)
- Indications Amyloidosis; Cardiomyopathies
- Focus Registrational; Therapeutic Use
- Acronyms ENDEAVOUR
- Sponsors Alnylam Pharmaceuticals
- 27 Jul 2017 According to an Alnylam Pharmaceuticals media release, the company will host its 4th annual series of "RNAi Roundtable" webcasts in summer and Fall 2017 and plans to present data from this trial in one of the webcasts (August 9, 2017).
- 10 Jun 2017 Biomarkers information updated
- 19 May 2017 This trial has been completed in Sweden (End date:2017-03-30) as per European Clinical Trials Database record.